Kymera Therapeutics (KYMR) Other Non Operating Income (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Other Non Operating Income of $15.0 million for Q1 2026, up 69.37% year-over-year from $8.8 million in Q1 2025, and up 37.25% quarter-over-quarter from $10.9 million in Q4 2025.
Kymera Therapeutics (KYMR) Other Non Operating Income (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Other Non Operating Income for 8 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 69.37% year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $44.2 million (up 18.31% YoY), while the FY2025 annual figure was $38.0 million, up 0.72% from the prior year.
- Other Non Operating Income advanced to $15.0 million in Q1 2026 per KYMR's latest filing, from $10.9 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $15.0 million in Q1 2026 and bottomed at $249000.0 in Q1 2022.
- Historically, Other Non Operating Income has averaged $6.8 million across 5 years, with a median of $7.9 million in 2025.
- Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 3318.18% — and 2025, when it declined 10.38%.
- Kymera Therapeutics' Other Non Operating Income stood at $3.6 million in 2022, then soared by 40.9% to $5.1 million in 2023, then surged by 94.61% to $10.0 million in 2024, then climbed by 9.12% to $10.9 million in 2025, then surged by 37.25% to $15.0 million in 2026.
- Business Quant data shows KYMR's Other Non Operating Income at $15.0 million in Q1 2026, $10.9 million in Q4 2025, and $10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.48 Mn |
| Mar 31, 2026 | 14.98 Mn |
| Dec 31, 2025 | 10.92 Mn |
| Sep 30, 2025 | 10.35 Mn |
| Jun 30, 2025 | 7.94 Mn |
| Mar 31, 2025 | 8.85 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 9.64 Mn |
| Jun 30, 2024 | 8.86 Mn |
| Mar 31, 2024 | 9.27 Mn |
| Dec 31, 2023 | 5.14 Mn |
| Sep 30, 2023 | 4.64 Mn |
| Jun 30, 2023 | 4.58 Mn |
| Mar 31, 2023 | 4.40 Mn |
| Dec 31, 2022 | 3.65 Mn |
| Sep 30, 2022 | 1.88 Mn |
| Jun 30, 2022 | 553,000.00 |
| Mar 31, 2022 | 249,000.00 |
| Dec 31, 2021 | 269,000.00 |
| Sep 30, 2021 | 55,000.00 |